Osiris surges 33.4% on 3Q sales boost
This article was originally published in Clinica
Executive Summary
Osiris Therapeutics closed up 33.4% at $17.76 per share on 1 November after the company reported $6.9m in product revenue for the third quarter of 2013. This represented a 220% jump in sales compared with the third quarter of 2012 for its stem cell-based wound healing and biosurgery products.